Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemiaShow others and affiliations
2024 (English)In: eJHaem, E-ISSN 2688-6146, Vol. 5, no 5, p. 998-1004Article in journal (Refereed) Published
Abstract [en]
Background
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease. Whereas some patients have an indolent disease, others experience an aggressive course and early death. Our aim was to investigate if modifiable and non-modifiable medical history and lifestyle factors prior to diagnosis had an impact on the natural course of the disease.
Method
In 1154 CLL patients, we assessed if the weight, physical activity, smoking, and alcohol consumption or non-modifiable characteristics including family history of lymphoid malignancy and medical history were associated with time-to-first-treatment (TTFT) and adjusted all results for the CLL-International Prognostic Index (CLL-IPI).
Results
TTFT was shorter for patients with high/very high-risk CLL-IPI than those with low/intermediate risk CLL-IPI. In the adjusted analysis we did not find additional impact on TTFT besides CLL-IPI from any environmental characteristics assessed.
Conclusions
We found limited impact of environmental factors on the natural course of CLL (measured as the TTFT in treatment na & iuml;ve patients) providing valuable knowledge, and potential relief, to share with patients at the time of diagnosis. How patients have lived their life (i.e. degree of physical activity, smoking and alcohol consumption) has no impact on the natural course of chronic lymphocytic leukemia (CLL), measured as time to first treatment, while CLL-international prognostic index (IPI) and its components strongly predicts prognosis. image
Place, publisher, year, edition, pages
John Wiley & Sons, 2024. Vol. 5, no 5, p. 998-1004
Keywords [en]
chronic lymphocytic leukemia, CLL-IPI, environmental factors, family history, IGHV mutation status, time-to-first-treatment
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-548061DOI: 10.1002/jha2.1000ISI: 001298239400001PubMedID: 39415908OAI: oai:DiVA.org:uu-548061DiVA, id: diva2:1929656
Funder
Swedish Research Council, 2022-00801Swedish Cancer Society, 19 0123 Pj 01 HKnut and Alice Wallenberg FoundationSwedish Research CouncilSwedish Cancer Society, 190109SCIASwedish National Institute of Public Health, R25 CA92049Swedish National Institute of Public Health, R01 AG58266Swedish National Institute of Public Health, P50 CA097274Swedish National Institute of Public Health, R01 CA92153Swedish National Institute of Public Health, R01 CA 200703Swedish National Institute of Public Health, R21CA256648Swedish Cancer Society, CAN 2012/774Swedish Cancer Society, 19 0425 Pj 01 HThe Cancer Research Funds of RadiumhemmetKarolinska Institute
Note
Ingrid Glimelius and Geffen Kleinstern contributed equally to the first authorship and Susan L. Slager and Karin E. Smedby contributed equally to the last authorship.
2025-01-212025-01-212025-01-21Bibliographically approved